Predicting vaccine effectiveness for mpox.

Autor: Berry MT; Kirby Institute, University of New South Wales, Sydney, NSW, Australia., Khan SR; Kirby Institute, University of New South Wales, Sydney, NSW, Australia., Schlub TE; Kirby Institute, University of New South Wales, Sydney, NSW, Australia.; Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia., Notaras A; Kirby Institute, University of New South Wales, Sydney, NSW, Australia., Kunasekaran M; Kirby Institute, University of New South Wales, Sydney, NSW, Australia., Grulich AE; Kirby Institute, University of New South Wales, Sydney, NSW, Australia., MacIntyre CR; Kirby Institute, University of New South Wales, Sydney, NSW, Australia.; College of Public Service and Community Solutions, and College of Health Solutions, Arizona State University, Tempe, AZ, USA., Davenport MP; Kirby Institute, University of New South Wales, Sydney, NSW, Australia. m.davenport@unsw.edu.au., Khoury DS; Kirby Institute, University of New South Wales, Sydney, NSW, Australia. dkhoury@kirby.unsw.edu.au.
Jazyk: angličtina
Zdroj: Nature communications [Nat Commun] 2024 May 08; Vol. 15 (1), pp. 3856. Date of Electronic Publication: 2024 May 08.
DOI: 10.1038/s41467-024-48180-w
Abstrakt: The Modified Vaccinia Ankara vaccine developed by Bavarian Nordic (MVA-BN) was widely deployed to prevent mpox during the 2022 global outbreak. This vaccine was initially approved for mpox based on its reported immunogenicity (from phase I/II trials) and effectiveness in animal models, rather than evidence of clinical efficacy. However, no validated correlate of protection after vaccination has been identified. Here we performed a systematic search and meta-analysis of the available data to test whether vaccinia-binding ELISA endpoint titer is predictive of vaccine effectiveness against mpox. We observe a significant correlation between vaccine effectiveness and vaccinia-binding antibody titers, consistent with the existing assumption that antibody levels may be a correlate of protection. Combining this data with analysis of antibody kinetics after vaccination, we predict the durability of protection after vaccination and the impact of dose spacing. We find that delaying the second dose of MVA-BN vaccination will provide more durable protection and may be optimal in an outbreak with limited vaccine stock. Although further work is required to validate this correlate, this study provides a quantitative evidence-based approach for using antibody measurements to predict the effectiveness of mpox vaccination.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: